Adicet Bio (ACET) to Release Earnings on Thursday

Adicet Bio (NASDAQ:ACET) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.6920) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last posted its earnings results on Wednesday, May 13th. The company reported ($1.88) EPS for the quarter, topping the consensus estimate of ($2.93) by $1.05. On average, analysts expect Adicet Bio to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Adicet Bio Price Performance

Shares of NASDAQ ACET opened at $9.24 on Tuesday. Adicet Bio has a fifty-two week low of $6.01 and a fifty-two week high of $17.44. The stock has a market cap of $86.39 million, a price-to-earnings ratio of -0.62 and a beta of 1.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.65 and a current ratio of 7.66. The firm’s 50-day simple moving average is $8.34 and its 200 day simple moving average is $7.80.

Hedge Funds Weigh In On Adicet Bio

Hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP bought a new position in shares of Adicet Bio in the third quarter valued at approximately $33,000. Squarepoint Ops LLC purchased a new position in Adicet Bio in the third quarter worth $38,000. Virtu Financial LLC purchased a new position in Adicet Bio in the third quarter worth $65,000. Citadel Advisors LLC grew its stake in Adicet Bio by 19.8% in the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock valued at $473,000 after purchasing an additional 96,342 shares during the period. Finally, Luminus Management LLC bought a new position in Adicet Bio in the 4th quarter valued at $501,000. Institutional investors own 83.89% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on ACET. Weiss Ratings raised Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. Jefferies Financial Group assumed coverage on Adicet Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $19.00 price target for the company. Finally, Wall Street Zen raised Adicet Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $48.80.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.